VIDEO: 'Exciting update' on pirtobrutinib for pretreated mantle cell lymphoma
Click Here to Manage Email Alerts
In this video, Joshua Brody, MD, discusses an update on pirtobrutinib for pretreated mantle cell lymphoma.
New data, presented at ASCO Annual Meeting, showed an overall response rate of 56.7%, and a high median duration of response at 17.6 months for the noncovalent Bruton tyrosine kinase inhibitor in patients who had previously been on an ineffective BTK inhibitor, Brody, director of the lymphoma immunotherapy program at the Tisch Cancer Institute at Mount Sinai, said.
Of the 56.7% who responded to the therapy with pirtobrutinib (Jaypirca, Eli Lilly & Co.), 19% were complete remissions. One year into therapy, the majority of patients continued to be in remission.
"With the early follow-up, I was skeptical at how good this data was when we heard about it at ASH last year and before," Brody said.
"More and more data just makes it absolutely more compelling," he said.
Reference :
- Shah NN, et al. Abstract 7514. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Read more about
Click Here to Manage Email Alerts